The aim of the study was to examine the effectiveness of the combination of etoposide with trastuzumab or pertuzumab in AGS gastric cancer cells with confirmed expression of HER2 [16] in comparison with monotherapy based on etoposide and untreated control. Here, ERBB2 is linked to gastric cancer.